This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACRX AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX) 30 days 90 days 365 days Advanced Chart Get AcelRx Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.49▼$0.8652-Week Range N/AVolume243,500 shsAverage Volume137,683 shsMarket Capitalization$14.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California. Read More Receive ACRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRX Stock News HeadlinesAcelRx Pharmaceuticals Q1 2025 Earnings PreviewMay 13, 2025 | msn.comTalphera’s Strategic Rebrand and Niyad’s Market Potential Bolster Buy RatingJanuary 11, 2024 | markets.businessinsider.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 7 at 2:00 AM | The Oxford Club (Ad)AcelRx announces rebranding with name change to TalpheraJanuary 9, 2024 | msn.comAcelRx Announces Rebranding With Name Change to Talphera, Inc.January 9, 2024 | finance.yahoo.comAcelRx Pharmaceuticals Stock (NASDAQ:ACRX) Dividends: History, Yield and DatesDecember 22, 2023 | benzinga.comAcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United StatesDecember 12, 2023 | finance.yahoo.comAcelRx Pharmaceuticals files for $150M mixed shelfNovember 22, 2023 | msn.comSee More Headlines ACRX Stock Analysis - Frequently Asked Questions How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.40). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to analyst estimates of $1.20 million. When did AcelRx Pharmaceuticals' stock split? Shares of AcelRx Pharmaceuticals reverse split before market open on Wednesday, October 26th 2022.The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of AcelRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/15/2021Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACRX CIK1427925 Webwww.acelrx.com Phone(650) 216-3500Fax650-216-6500Employees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$47.76 million Net MarginsN/A Pretax Margin-3,711.25% Return on Equity-81.54% Return on Assets-46.02% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual Sales$1.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / BookN/AMiscellaneous Outstanding Shares16,950,000Free Float16,443,000Market Cap$14.58 million OptionableOptionable Beta0.52 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ACRX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AcelRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AcelRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.